Floatz logo

FULVESTRANT

CCCA Assessed by Ki67 Drop Below <2.7% From Baseline

GBG Forschungs GmbHSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the CCCA Assessed by Ki67 Drop Below <2.7% From Baseline cohort.

Asset / SponsorPhaseRating
Capivasertib
GBG Forschungs GmbH
Phase 2CCC

Same molecule, other indications

FULVESTRANT is also rated in:

Hormone Receptor Positive TumorDormant
BB
Indicative ·
70 / 100
View asset →
hormone receptor-positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
Progesterone Receptor PositiveDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →